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Introduction
Juvenile Dermatomyositis is a rare Pediatric Rheumatic
Disease, associated with significant morbidity. Evidence-
based guidelines are sparse and management is mostly
based on physician’s experience. Consequently, treatment
regimens differ throughout Europe. In 2012, a European
initiative called SHARE (Single Hub and Access point for
pediatric Rheumatology in Europe) was launched to opti-
mize and disseminate diagnostic and management regi-
mens in Europe for children and young adults with
rheumatic diseases.
Objectives
One of the aims of SHARE was to provide evidence-based
recommendations for diagnosis and treatment of JDM.
Methods
Evidence based recommendations were developed using
the European League Against Rheumatism (EULAR) stan-
dard operating procedure (1). An expert committee was
instituted, consisting of pediatric rheumatologists and
experts in pediatric exercise physiology and physical ther-
apy. The expert committee defined search terms for the
systematic literature review. Two independent experts
scored articles for validity and level of evidence. Recom-
mendations derived from the literature were evaluated by
an online survey. Those with less than 80% agreement
during the online survey were reformulated. Subsequently,
all recommendations were discussed at a consensus meet-
ing using nominal group technique [2]. Recommendations
were accepted if more than 80% agreement was reached.
Results
The literature search yielded 3280 articles, of which 108
(63 for diagnosis and 44 for treatment) were considered
relevant and therefore scored for validity and level of evi-
dence. 77 articles (55 for diagnosis and 22 for treatment)
were scored valid and used in the formulation of the
recommendations. 21 recommendations for diagnosis and
7 for treatment were suggested in the online survey. Dur-
ing the consensus meeting, recommendations were dis-
cussed and re-formulated where applicable. It was agreed
that all children with suspected inflammatory myopathies
should be referred to a specialist centre, with immediate
referral for defined high-risk patients. In addition to this,
20 evidence-based recommendations for diagnosis and 9
for treatment were accepted with more than 80% agree-
ment. Topics covered for diagnosis, included assessment
of skin involvement, muscle involvement including muscle
biopsy, MRI and muscle testing, lung involvement, auto-
antibodies, and biomarkers. Treatment recommendations
included initial treatment of newly diagnosed patients and
therapy for severe disease.
Conclusion
The SHARE initiative provides recommendations for
diagnosis and treatment for JDM and thereby facilitates
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